Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) have been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $55.00.

Several analysts have recently weighed in on FTH shares. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price target on the stock. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd.

Insider Transactions at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was acquired at an average cost of $23.50 per share, with a total value of $117,500.00. Following the completion of the acquisition, the chief financial officer owned 46,688 shares of the company’s stock, valued at $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of the stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the transaction, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. The trade was a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 49,494 shares of company stock valued at $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after buying an additional 1,100 shares during the period. Citadel Advisors LLC acquired a new position in Sensei Biotherapeutics in the 2nd quarter valued at about $307,000. Bank of America Corp DE increased its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Stempoint Capital LP purchased a new stake in Sensei Biotherapeutics during the 1st quarter valued at approximately $4,188,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics during the 2nd quarter valued at approximately $3,610,000. 10.50% of the stock is owned by hedge funds and other institutional investors.

Sensei Biotherapeutics Stock Performance

FTH opened at $40.05 on Monday. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $41.16. The stock has a market cap of $1.03 billion, a P/E ratio of -0.28 and a beta of -0.28. The firm has a 50-day simple moving average of $29.86.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. Analysts forecast that Sensei Biotherapeutics will post -13.18 EPS for the current year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.